Drug Royalties Co. Ramps Up Issuance
Ontario-based DRI Capital is preparing a securitization from its portfolio of royalties from pharmaceutical and bio-tech patents, following up its March ABS issuance and marking an accelerated issuance strategy for the company.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: